Surgery versus external beam radiotherapy for hepatocellular carcinoma involving the inferior vena cava or right atrium: A systematic review and meta-analysis

^{1†}**Han-Ah Lee**, ^{2†}**Sunmin Park**, ¹**Yeon Seok Seo**, ²**Won Sup Yoon**, ³**In-Soo Shin**, ²**Chai Hong Rim**

¹Department of Gastroenterology, Korea University Anam Hospital, Korea University Medical College, Seoul, Korea

²Department of Radiation oncology, Korea University Ansan Hospital, Korea University Medical College, Gyeonggi-do, Korea

³Graduation school of Education, Dongguk University, Seoul, Korea

[†]These authors equally contributed to the study.

Corresponding author: Prof. Chai Hong Rim.

Department of Radiation Oncology, Ansan Hospital, Korea University,
123 Jeokgeum-ro, Danwon-gu, Ansan, Gyeonggi-do, 15355, Republic of Korea
Tel: +82 31 412 6850; Fax: +82 31 412 6851; Email: crusion3@naver.com

Abbreviations: CI, confidence interval; CPC, Child-Pugh class; EBRT, external beam radiotherapy; IVC, inferior vena cava; HCC, hepatocellular carcinoma; OS, overall survival; PVT, portal vein thrombosis; RA, right atrium; TACE, transarterial chemoembolization.

Abstract

Purpose: As the treatment efficacy of systemic therapy for patients with advanced-stage HCC is insufficient, locoregional therapies are performed in the clinical practice. We investigated the efficacy and safety of two most potent therapies, surgery and external beam radiotherapy (EBRT), in patients with HCC involving the IVC and/or right atrium (RA) through comparative meta-analysis.

Method: A systematic search of Pubmed, MEDLINE, EMBASE, and the Cochrane library was performed for entries up to July 2020. The primary endpoints were 1- and 2-year overall survival (OS) rates, while secondary endpoints were response rate, local control rate, and grade ≥ 3 toxicities.

Results: Eighteen studies with 22 cohorts were included, encompassing 755 patients. The pooled median OS and 1-and 2-year OS rates were 14.2 months, 55.6%, and 27.4%, respectively. The pooled median OS in the surgery and EBRT arms were 15.3 and 11.7 months, respectively. The pooled 1-year OS rate of the surgery arm was significantly higher than that of the EBRT arm (62.4%, 95% CI: 53.8–70.3 vs. 48.8%, 95% CI: 40.9–56.8; $p=0.023$). However, the 2-year OS rates were comparable (26.9%, 95% CI: 20.7–34.2 vs. 27.5%, 95% CI: 19.7–37.1; $p=0.913$). The pooled response and local control rates in the EBRT arm were 74.3% and 87.2%, respectively. In the surgical arm, the perioperative mortality and grade ≥ 3 complication rates were 0–7.6% and 3.9–67%, respectively. Grade ≥ 3 complications and radiation-induced liver disease were rarely observed in the EBRT arm.

Conclusions: Both surgery and EBRT are effective treatment options for patients with HCC involving IVC/RA invasion. Outcomes and safety should be further evaluated in well-controlled clinical trials.

Keywords: Hepatocellular carcinoma, Inferior vena cava, Meta-analysis, Radiotherapy, Surgery

Introduction

HCC is the sixth most common cancer and fourth major cause of cancer-related deaths worldwide [1]. The prevalence of HCC varies among regions; approximately 75% of HCCs occur in East Asia, where the major risk factor is chronic hepatitis B infection [2]. In contrast to patients in other geographic areas, a considerable number of those in East Asia are diagnosed with advanced stage despite active HCC surveillance [3].

It is well known that patients with macrovascular invasion have poor prognoses, with median survival times of 6–8 months when untreated [4, 5]. Compared to the portal vein, HCC less frequently involves the IVC and right atrium (RA); under 4% of all HCC patients have such involvement [6-8] but experience worse outcomes with expected survival times of less than 3 months without treatment [9]. In addition, IVC tumor thrombi can flow into the heart and lungs, causing pulmonary embolisms and lung metastases [10-12].

Although most guidelines recommend systemic therapy as the standard treatment for advanced-stage HCC [13], such treatments provide minimal or modest clinical benefits [14, 15]. Furthermore, other local treatments such as surgical resection or external beam radiotherapy (EBRT) have produced comparable or better efficacies than sorafenib in several studies of patients presenting with major vascular invasion [16, 17]. Hence, the use of systemic therapy as the first-line treatment is not prevalent, and many clinicians have attempted to reduce the tumor burden with locoregional therapies in real-world practice [18].

A standardized treatment for HCC involving the IVC/RA has not been established owing to a limited number of studies to date. Following advances in surgical techniques, recent studies showed that surgical management of these patients produced better survival outcomes than non-surgical alternatives. However, since surgical approaches for this group of patients are invasive, complete resection is not always possible, and it is necessary to balance between effectiveness and avoiding complications [19-21]. Although transarterial chemoembolization (TACE) is the most common local treatment modality, its oncologic outcome is unsatisfactory given its median survival of 4.2–4.7 months [22-24]. Since EBRT is feasible for treating HCC lesions including those in major vessels, it

has also been performed in patients with IVC/RA involvement and was found to be effective and safe in a recent meta-analysis, dispelling previous belief that EBRT can lead to pulmonary embolism or cardiac toxicity [17].

Although surgical resection and EBRT have been considered potent treatment options for patients with HCC who have IVC/RA invasion, adequate comparative studies have not been conducted. Therefore, we performed this comparative meta-analysis to evaluate the efficacies and feasibilities of both surgical approach and EBRT for HCC patients with IVC/RA invasion.

Methods

Database search and study selection

The present systematic review and meta-analysis was designed to answer *the following PICO question:*

“Are surgical approach and EBRT for HCC patients with IVC and/or RA invasion comparable options regarding oncologic efficacy and feasibility?” Four databases (EMBASE, Medline, Pubmed, and the Cochrane library) were systematically searched for literature published up to July 8th, 2020.

Publications prior to the year 2000 were excluded; no language restriction was applied. Conference abstracts were not considered owing to the lack of clinical data that compare between treatment modalities. Detailed search strategies, including the search terms used, are shown in Supplement 1.

Studies included in the present analyses met the following criteria: 1) clinical studies involving at least 10 patients with HCC who have IVC and/or RA invasion and were treated with either surgery or EBRT, and 2) survival outcomes were detailed. Multiple studies from the same institution were all included if patient overlap was either not present or negligible; if patient overlap was significant, the following criteria were used for selection, prioritized in the order listed: 1) studies involving HCC patients with IVC and/or RA invasion exclusively (i.e., not those in which such invasion were subgroups or prognosticators); 2) larger number of patients; and 3) more recently published.

After the initial search, studies with irrelevant formats (e.g., reviews, letters, conference abstracts, editorials, case reports, trial protocols, and lab studies) were excluded using machine filtering

functions provided by EMBASE and PubMed. Duplicate studies were filtered out using the Rayan QCRI web-based program (<https://rayyan.qcri.org/welcome>). Initial searches across databases and machine filtering were performed by an experienced meta-analysis researcher (CHR). Next, abstract and full-text reviews were performed by 2 independent researchers to identify suitable studies. The studies that were finally included were verified by all authors.

Data acquisition

Data were recorded on a pre-standardized coding sheet that included 1) general information (author names, affiliations, publication year, funding sources); 2) clinical data including age, etiology, Child-Pugh class, (CPC), alpha-fetoprotein level, accompanying PVT rate, extrahepatic metastasis rate, tumor size, radiotherapy (RT) method, complete resection rate, pre-, combined, or post-treatment; and 3) the primary endpoint of overall survival (OS) as well as secondary endpoints that included response rate after EBRT, first progression site, grade ≥ 3 complications, and perioperative mortality. In the absence of numeral data, OS rates were estimated using descriptive graphs. Two independent researchers acquired the data, and any disagreements were resolved with mutual discussion and a re-review of the literature.

Quality assessment and statistical methods

Considering that most studies of patients with HCC are non-randomized clinical series, we used the Newcastle-Ottawa scale for quality assessment [25]. Studies with scores of 7 to 9 were considered high quality and those with scores of 4 to 6 were deemed medium quality. Considering that a vast majority of studies shared a similar design, no specific method to differentiate studies based on data synthesis (e.g., different weighting or subgroup analyses according to the studies' qualities) was applied. This meta-analysis included studies at the outcome level. Although it targeted a rare type of HCC, there can still be significant distinctions in terms of clinical characteristics and treatment details; therefore, a random effects model was used for all pooled estimates.

All endpoints of interest were measured as rates (percentages), and pooled rates were calculated as the

weighted averages of those rates. The exception was that grade ≥ 3 complications and perioperative mortality rates were analyzed qualitatively. Heterogeneity among studies was assessed using Cochran's Q test [26] and I^2 statistics [27]. I^2 values of 25%, 50%, and 75% corresponded to low, moderate, and high heterogeneity, respectively. Publication bias was assessed by visual inspection of funnel plots and quantitative analyses using Egger's test [28]. If significant asymmetry was observed and the 2-tailed p-value in Egger's test was lower than 0.1, Duval and Tweedie's trim and fill was performed for sensitivity analysis [29]. Subgroup comparisons were performed using mixed effects analyses and Cochran's Q-test, based on analysis of variance. Subgroup analyses were performed to examine local treatment methods (surgery vs. EBRT) as well as known clinical prognosticators including CPC-A, accompanying PVT, and extrahepatic metastases [17, 30]. Borderline values between subgroups were set close to the overall median value. The p-values <0.05 were considered significant on subgroup analyses. Statistical analyses were performed by an experienced meta-analysis researcher (CHR) and supervised by a biostatistician specialized in meta-analyses (ISS). All statistical analyses were performed using Comprehensive Meta-Analysis version 3 (Biostat Inc., Englewood, NJ, USA).

Results

Study inclusion and general information

The initial database searches identified 1139 articles; however, initial machine filtering excluded 879 studies with irrelevant formats as well as 25 duplicates. Next, 235 studies underwent abstract screening; among them, 207 were excluded after investigation by 2 independent researchers. Full-text reviews of 28 articles were performed, and 18 studies of 22 cohorts involving 755 patients were ultimately included in the present study. The study selection process is shown in Figure 1.

Among the 18 studies, 8 were single arm studies [19-22, 31-34] that were categorized into the surgery subgroup, another 8 were single arm studies [24, 35-41] categorized into the EBRT subgroup, and 2 were controlled studies [42, 43] comprising 2 cohorts that compared surgery and EBRT. Eight studies (44%) were from mainland China, 6 from Japan (33%), 2 from Korea (11%), and 1 from Taiwan

(5.6%). A vast majority of patients in the studies performed in China, Korea, and Taiwan had HCC related to hepatitis B virus, while the proportions of patients with HCC related to hepatitis B and C viruses were comparable in studies from Japan. The rates of patients with CPC-A ranged from 72.9% to 100% (median: 100%) in the surgery arm and from 44.4% to 88.0% (median: 60.7%) in the EBRT arm. The median rates of PVT were 48.0% (range: 0%–100%) and 32.5% (range: 0%–100%) in the surgery and EBRT arms, respectively, while the corresponding rates of extrahepatic metastases (including lymph node metastasis) were 10.7% (range: 0–61.5%) and 30.8% (range: 0–94.6%), respectively. Data from the studies are shown in Table 1.

Quality analysis

All studies were deemed medium quality except for 2 controlled studies by Li et al. [42] and Komatsu et al. [43] that were high quality. All medium-quality studies lacked points for the selection of non-exposed cohorts and comparability between cohorts; detailed results are shown in Supplement 2. Funding information was available for 16 of the 18 studies. Eight studies were supported by the government, 2 by academic funding, and 6 received no funding. None of the studies reported conflicts of interest regarding commercial ties (Table 1).

Clinical data and outcomes of interest

The median OS periods were 14.2 months (range: 5–21 months), 15.3 months (range: 13.0–19.0 months), and 11.7 months (range: 5.6–21.0 months) for all studies, the surgery arms, and EBRT arms, respectively. Among the 8 studies that reported prognostic factors related to OS, tumor multiplicity was reported in 4 studies, extrahepatic metastasis in 3, and CPC in 3. The most common sites of first progression were the liver (21.5–61.5%) and lung (13.5–42.9%). TACE and chemotherapy were the most common modalities applied pre- or post-surgery or radiotherapy. Li et al. (1 of the 2 controlled trials) reported that the median OS was similar in both the surgery and EBRT arms (14.5 vs. 12.8 months, $p=0.466$), while Komatsu et al. (the other controlled trial) demonstrated that the 1-year OS was lower in the surgical arm than in the EBRT arm with a non-significant trend (25% vs. 68%,

$p=0.106$). Clinical data from the included studies are shown in Table 2.

The surgery arm had a higher pooled rate of patients with CPC-A than did the EBRT arm (90.1%, 95% CI: 80.2–95.4 vs. EBRT: 70.0%, 95% CI: 56.9–80.5; $p=0.007$) and had a lower rate of patients with extrahepatic metastases (14.5%, 95% CI: 7.6–25.8 vs. 34.5%, 95% CI: 16.5–58.3, $p=0.067$). The pooled 1- and 2-year OS rates for all studies were 55.6% (95% CI: 48.9–62.1) and 27.4% (95% CI: 22.3–33.1), respectively. The surgery arm had a higher 1-year OS rate (62.4%, 95% CI: 53.8–70.3) than did the EBRT arm (48.8%, 95% CI: 40.9–56.8) ($p=0.023$), although the 2-year OS rates were similar (26.9%, 95% CI: 20.7–34.2 vs. 27.5%, 95% CI: 19.7–37.1; $p=0.913$). On subgroup analyses, patients with lower extrahepatic metastasis rates ($<20\%$ vs. $\geq 20\%$) showed higher 1-year OS rates with borderline significance (62.7% vs. 50.6%, $p=0.072$). Pooled results are shown in Table 3 and depicted as forest plots in Figure 2.

As for secondary endpoints, the most common sites of first progression were the liver (pooled rate: 43.2%, 95% CI: 31.0–56.2), followed by the lung (pooled rate: 34.0%, 95% CI: 24.6–44.9). The pooled rates of complete remission, response rate, and local control after EBRT were 27.9% (95% CI: 15.5–45.0), 74.3% (95% CI: 46.9–90.5), and 87.2% (95% CI: 78.2–92.8), respectively (Table 4). Four studies in the surgery arm reported either 30-day or 90-day perioperative mortality rates, which ranged from 0 to 7.6%. Grade ≥ 3 complication rates were reported in 5 surgery cohorts and ranged from 3.9% to 67%. Radiation-induced liver disease was very rare, having been reported in only 1 study (2% rate). Grade ≥ 3 complications in the EBRT arm were nonexistent (0%) in all cohorts except Rim et al.'s study [36], wherein the rates of gastrointestinal complications, ascites, and varices were 0%, 2%, and 2%, respectively. In that same study, the rates of transient elevation of liver function markers (e.g., albumin, bilirubin, and aspartate transaminase/alanine transaminase: 30.6%) and decrease in blood count (e.g., white blood cells, hemoglobin, and platelets: 26.5%) were relatively high (Table 2).

Heterogeneity and publication bias analyses

Heterogeneity among cohorts was moderate-to-high in most of the pooled analyses except on subgroup analyses of 1- and 2-year OS rates in patients with high alpha-fetoprotein and of the 1-year OS rate in the patients with low PVT rates. Potential publication bias was not evident in the pooled analysis of the 1-year OS rate, but was noted for that of the 2-year OS rate; the 2-tailed p-value in Egger's test was 0.078, and the trimmed value using Duval and Tweedie's method was increased from the original value (pooled 2-year OS rate: 27.4% to 32.3%) (Table 3). Funnel plots are shown in Figure 2.

Discussion

Patients with HCC that includes IVC/RA invasion have a poor prognosis and risk life-threatening complications. Although pioneering researchers have applied active local treatments to improve clinical outcomes, previous data were not sufficient to derive optimal treatment strategies. In this comparative meta-analysis, we evaluated the therapeutic effect and safety of the 2 most promising treatment modalities, surgical resection and EBRT, for patients with HCC involving the IVC/RA.

Our study had several clinical strengths and implications. Our pooled median OS was 14.2 months, which is much longer than that of previous series [22-24, 44, 45]. Chun et al. [44] showed that the median OS of patients with IVC/RA invasion was 4 and 2 months in the actively treated and supportive care groups, respectively. In the active treatment group, only 18.7% of patients underwent surgery or EBRT, whereas approximately half of the patients underwent 5-fluorouracil-based chemotherapy or TACE. When compared to the median OS in studies of patients treated with TACE (4.2–4.7 months) [22-24], the treatment efficacy of surgery and EBRT appeared to be superior to that of TACE alone. In the same vein, Wang et al. [22] compared the survival benefits of surgery and TACE in a matched cohort comparison; the median survival times were 19 vs. 4.5 months ($p < 0.001$). Koo et al. [24]. also demonstrated that combined TACE and EBRT yielded higher survival than the control group that underwent TACE alone (median survival: 11.7 vs. 4.7 months, $p < 0.01$).

The median survival of patients in the surgery arm in our study was 15.3 months, which was longer than 11.7 months in the EBRT arm; this suggests that surgery might produce a greater survival benefit than EBRT for these patients. However, caution is needed when interpreting this result because there were significantly more patients with CPC-A (90.1% vs. 70.0%, $p=0.007$) while extrahepatic metastases tended to be less common (14.5% vs. 34.5%, $p=0.067$) in the surgery arm. Impaired liver function and the presence of extrahepatic metastasis are known predictors of poor prognosis in patients with advanced-stage HCC [46]. Therefore, to reduce the effects of selection bias and confounding factors on survival, a well-designed propensity score-matched study is required. Indeed, in the study by Li et al. that compared the treatment effects of surgery and RT in patients without extrahepatic metastasis and with similar characteristics between groups, no significant difference in survival was observed (median survivals with surgery vs. EBRT: 14.5 vs. 12.8 months, $p=0.466$) [21]. A study by Komatsu et al. also showed comparable survival outcomes ($p=0.106$) in the surgery and EBRT groups following matched-pair analysis that adjusted for 12 clinical factors [43].

In contrast to the significantly higher 1-year OS rate in the surgery arm than in the EBRT arm (62.4% vs. 48.8%, $p=0.023$), the 2-year OS rates in the 2 groups were comparable (26.9% vs. 27.5%, $p=0.913$). Although most surgeries aim to remove all tumor lesions, advanced-stage HCCs may not be completely resectable and can remain macroscopic tumor or microscopic metastases. Even after curative resection, early recurrence (which characteristically occurs within 2 years after treatment) is frequent in patients with advanced-stage HCC [47, 48], and this may contribute to considerable differences in mortality between 1 and 2 years among those who undergo surgical resection [49, 50]. Indeed, 1-year recurrence-free survival in studies where surgery was applied ranged from 26% to 44% [19, 20, 31, 32].

The pooled response and local control rates following EBRT (the secondary outcomes of our study), were 74.3% and nearly 90%, respectively, demonstrating potent local control with EBRT. With the introduction of 3-dimensional conformal radiation therapy, it has become possible to apply therapeutic doses of 45–60 Gy to the tumor while sparing the normal liver. Therefore, the treatment efficacy for liver malignancies has markedly increased [51-53]. EBRT can be safely applied for

tumors that involve major vessels, with a tolerance dose of over 100 Gy, whereas other modalities may be contraindicated owing to possible hemorrhage [54]. Objective response or local control of IVC/RA after EBRT was shown to be significantly related to survival [24, 41]. Therefore, EBRT could be an effective treatment modality, possibly enhancing the oncologic outcomes of these patients. Additionally, the pooled response and local control rates of HCCs that invaded the IVC/RA were higher than those of HCCs with PVTs in previous studies [55]. This phenomenon could be explained by the difference between the portal and hepatic veins, as the components of the PVT (tumor and blood cells that block the narrow-diameter vessels) are less affected by EBRT than are the isolated tumor thrombi in the IVCs [37, 56].

Although the surgery arm demonstrated higher median and 1-year survival rates, the grade ≥ 3 complication rates in this arm were higher than those in the EBRT arm (3.9–67% vs. 0–4%); moreover, post-operative mortality rates of 0–7.6% were observed in the former. For radical resection of HCCs involving the IVC/RA, concerns exist regarding the burden on the circulatory system that arises owing to invasive procedures, such as total hepatic vascular exclusion or extracorporeal circulation. Furthermore, pulmonary embolisms and pleural effusions, which are closely associated with circulatory dysfunction, commonly develop [19, 20, 22]. There are also concerns that EBRT for treating IVC/RA thromboses might cause systemic complications, such as pulmonary embolism or cardiac failure. However, most studies in the EBRT arm showed an absence or a very low rate of grade ≥ 3 complications (including radiation-induced liver disease). This may be due to successfully limiting the bystander radiation dose to adjacent major organs (such as the lung and heart) to levels lower than the standardized dose constraints [13, 57]. In addition, duodenal toxicity, which is a common and serious complication when treating HCC with EBRT, is less a concern because of the longer distance between the IVC/RA thrombosis and duodenum [54]. Given these safety issues, surgery could be considered for patients with favorable clinical characteristics, whereas EBRT could be a less invasive alternative option that has potent treatment efficacy.

Lastly, the most common sites of first progression after local control using EBRT were the liver (43.2%) and lung (34.0%), as expected. In the multi-institutional study by Rim et al. [36], which is

one of the largest EBRT series, the median progression-free survival after EBRT was only 4 months in patients with HCC exhibiting IVC/RA invasion. After surgical resection, the median recurrence-free survival only reached 5.2–5.3 months [19, 20, 31, 32]. When considering the short time before the disease progressed, local control may not be sufficient to prevent further progression in substantial patients with advanced-stage HCC, therefore, there is a distinct need for preventing further HCC progression after local treatment. Studies evaluating the effect of systemic therapy after local control in advanced-stage HCC are scarce. Rim et al. reported that patients who had concurrent or additional systemic treatment had longer median overall survival than those without such treatment (12.2 vs. 8.4 months, $p=0.054$); however, the trend was not significant [17]. Kasai et al. evaluated the effect of adjuvant sorafenib therapy after surgical resection in patients with HCC involving the IVC/RA and showed comparable OS and recurrence-free survival between patients with and without adjuvant therapy [20].

Recently, the immune-related effects of RT have gained attention in the era of immunotherapy because RT may have pro-immunogenic effects on immune responses [58]. Preclinical data demonstrated that RT could improve the response of cancer cells to immune checkpoint inhibitors by enhancing immunogenic antigen presentation, stimulating proinflammatory cytokines, and increasing PD-L1 expression [59]. The results of several ongoing clinical trials that are evaluating the effect of EBRT alone or in combination with systemic therapies could provide valuable perspectives to clinicians.

We are also aware of several limitations that remained unresolved. Meta-analyses of non-randomized studies are controversial because the pooled effects can be influenced by different study designs and patient characteristics [60]. Regarding our present study, detailed methods of surgery or radiotherapy varied among institutions, and there would have been differences in the application of additional treatments aside from the main local modalities. Although a large randomized trial might provide robust evidence with minimal biases, the field of oncology does not always provide the best evidence, and clinical decisions are commonly based on small or observational studies [61]. HCC involving the

IVC/RA is a very rare condition with a poor prognosis; therefore, a meta-analysis of observational studies might be one of the few available methods to assess treatment efficacy and feasibility.

In conclusion, both surgery and EBRT are effective treatment options for patients with HCC exhibiting IVC/RA invasion. Surgical resection appears to provide a longer survival benefit than EBRT; however, its higher rate of complications should also be considered. EBRT could be safely used in patients with HCC involving the IVC/RA as a feasible and effective palliative treatment option. Further studies comparing the efficacy and safety of surgical resection and EBRT in well-controlled patient groups are warranted.

Declaration

Funding: This study was supported by the National Research Fund of Korea (NRF-2019M2D2A1A01031560). The research grant supported only methodological aspects including statistical analysis and linguistic correction, and did not influence major contents including the results and conclusions.

Ethical considerations: Ethical approval was not required because this study retrieved and synthesized data from papers that are already published.

Conflicts of interest: None of the authors have any conflicts of interest to disclose.

Author contributions: **Han Ah Lee**, writing-original draft, writing-review & editing; **Sunmin Park**, data curation, writing-review & editing; **Yeon Seok Seo**, supervision; **Won Sup Yoon**, supervision; **In-Soo Shin**, methodology; **Chai Hong Rim**, conceptualization, writing-original draft, writing-review & editing, formal analysis, data curation

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394-424.
2. Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int*. 2017;11(4):317-70.
3. Lee J, Yoon WS, Koom WS, Rim CH. Role of local treatment including radiotherapy in Barcelona Clinic of Liver Cancer stage C patients: a nationwide cohort analysis in South Korea. *Cancer Manag Res*. 2019;11:1373-82.
4. Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. *Hepatology*. 2010;51(4):1274-83.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology*. 2003;37(2):429-42.
6. Lee IJ, Chung JW, Kim HC, Yin YH, So YH, Jeon UB, et al. Extrahepatic collateral artery supply to the tumor thrombi of hepatocellular carcinoma invading inferior vena cava: the prevalence and determinant factors. *J Vasc Interv Radiol*. 2009;20(1):22-9.
7. Kojiro M, Nakahara H, Sugihara S, Murakami T, Nakashima T, Kawasaki H. Hepatocellular carcinoma with intra-atrial tumor growth. A clinicopathologic study of 18 autopsy cases. *Arch Pathol Lab Med*. 1984;108(12):989-92.
8. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. *Cancer*. 1954;7(3):462-503.
9. Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. *International journal of radiation oncology, biology, physics*. 2005;61(2):432-43.
10. Lin HH, Hsieh CB, Chu HC, Chang WK, Chao YC, Hsieh TY. Acute pulmonary embolism as the first manifestation of hepatocellular carcinoma complicated with tumor thrombi in the inferior vena cava: surgery or not? *Dig Dis Sci*. 2007;52(6):1554-7.
11. Papp E, Keszthelyi Z, Kalmar NK, Papp L, Weninger C, Tornoczky T, et al. Pulmonary embolization as primary manifestation of hepatocellular carcinoma with intracardiac penetration: a case report. *World J Gastroenterol*. 2005;11(15):2357-9.
12. Saynak M, Ozen A, Kocak Z, Cosar-Alas R, Uzal C. Sudden death: a case report of hepatocellular carcinoma with tumor thrombus extending into the right atrium. *J buon*. 2007;12(4):556.
13. Park S, Yoon WS, Rim CH. Indications of external radiotherapy for hepatocellular carcinoma from updated clinical guidelines: Diverse global viewpoints. *World J Gastroenterol*. 2020;26(4):393-403.
14. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial. *Expert Rev Anticancer Ther*. 2009;9(6):739-45.
15. Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib

Asia-Pacific trial. *Eur J Cancer*. 2012;48(10):1452-65.

16. Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, et al. Liver resection for hepatocellular carcinoma associated with hepatic vein invasion: A Japanese nationwide survey. *Hepatology*. 2017;66(2):510-7.

17. Rim CH, Kim CY, Yang DS, Yoon WS. External beam radiation therapy to hepatocellular carcinoma involving inferior vena cava and/or right atrium: A meta-analysis and systemic review. *Radiother Oncol*. 2018;129(1):123-9.

18. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. *Liver Int*. 2015;35(9):2155-66.

19. Matsukuma S, Eguchi H, Wada H, Noda T, Shindo Y, Tokumitsu Y, et al. Liver resection with thrombectomy for patients with hepatocellular carcinoma and tumour thrombus in the inferior vena cava or right atrium. *BJS open*. 2020;4(2):241-51.

20. Kasai Y, Hatano E, Seo S, Taura K, Yasuchika K, Okajima H, et al. Proposal of selection criteria for operative resection of hepatocellular carcinoma with inferior vena cava tumor thrombus incorporating hepatic arterial infusion chemotherapy. *Surgery*. 2017;162(4):742-51.

21. Li AJ, Zhou WP, Lin C, Lang XL, Wang ZG, Yang XY, et al. Surgical treatment of hepatocellular carcinoma with inferior vena cava tumor thrombus: a new classification for surgical guidance. *Hepatobiliary & pancreatic diseases international : HBPD INT*. 2013;12(3):263-9.

22. Wang Y, Yuan L, Ge RL, Sun Y, Wei G. Survival benefit of surgical treatment for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: results of a retrospective cohort study. *Annals of surgical oncology*. 2013;20(3):914-22.

23. Chern MC, Chuang VP, Cheng T, Lin ZH, Lin YM. Transcatheter arterial chemoembolization for advanced hepatocellular carcinoma with inferior vena cava and right atrial tumors. *Cardiovasc Intervent Radiol*. 2008;31(4):735-44.

24. Koo JE, Kim JH, Lim YS, Park SJ, Won HJ, Sung KB, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. *International journal of radiation oncology, biology, physics*. 2010;78(1):180-7.

25. Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. Newcastle-Ottawa quality assessment scale cohort studies. 2014.

26. Cochran WG. The Combination of Estimates from Different Experiments. *Biometrics*. 1954;10(1):101-29.

27. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002;21(11):1539-58.

28. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Br Med J*. 1997;315(7109):629-34.

29. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. *Biometrics*. 2000;56(2):455-63.

30. Rim CH, Yim HJ, Park S, Seong J. Recent clinical applications of external beam radiotherapy for hepatocellular carcinoma according to guidelines, major trials and meta-analyses. *J Med Imaging Radiat Oncol*.

2019;63(6):812-21.

31. Zhang XP, Liu YC, Chen ZH, Sun JX, Wang K, Chai ZT, et al. Postoperative Adjuvant Transarterial Chemoembolization Improves Outcomes of Hepatocellular Carcinoma Associated with Hepatic Vein Invasion: A Propensity Score Matching Analysis. *Annals of surgical oncology*. 2019;26(5):1465-73.
32. Kokudo T, Hasegawa K, Yamamoto S, Shindoh J, Takemura N, Aoki T, et al. Surgical treatment of hepatocellular carcinoma associated with hepatic vein tumor thrombosis. *Journal of hepatology*. 2014;61(3):583-8.
33. Wakayama K, Kamiyama T, Yokoo H, Kakisaka T, Kamachi H, Tsuruga Y, et al. Surgical management of hepatocellular carcinoma with tumor thrombi in the inferior vena cava or right atrium. *World journal of surgical oncology*. 2013;11:259.
34. Liu J, Wang Y, Zhang D, Liu B, Ou Q. Comparison of survival and quality of life of hepatectomy and thrombectomy using total hepatic vascular exclusion and chemotherapy alone in patients with hepatocellular carcinoma and tumor thrombi in the inferior vena cava and hepatic vein. *European journal of gastroenterology & hepatology*. 2012;24(2):186-94.
35. Duan F, Yu W, Wang Y, Liu FY, Song P, Wang ZJ, et al. Trans-arterial chemoembolization and external beam radiation therapy for treatment of hepatocellular carcinoma with a tumor thrombus in the inferior vena cava and right atrium. *Cancer imaging : the official publication of the International Cancer Imaging Society*. 2015;15(1):7.
36. Rim CH, Jeong BK, Kim TH, Hee Kim J, Kang HC, Seong J. Effectiveness and feasibility of external beam radiotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium involvement: a multicenter trial in Korea (KROG 17-10). *International journal of radiation biology*. 2020;96(6):759-66.
37. Hou JZ, Zeng ZC, Zhang JY, Fan J, Zhou J, Zeng MS. Influence of tumor thrombus location on the outcome of external-beam radiation therapy in advanced hepatocellular carcinoma with macrovascular invasion. *International journal of radiation oncology, biology, physics*. 2012;84(2):362-8.
38. Igaki H, Nakagawa K, Shiraishi K, Shiina S, Kokudo N, Terahara A, et al. Three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava invasion. *Japanese journal of clinical oncology*. 2008;38(6):438-44.
39. Sekino Y, Okumura T, Fukumitsu N, Iizumi T, Numajiri H, Mizumoto M, et al. Proton beam therapy for hepatocellular carcinoma associated with inferior vena cava tumor thrombus. *Journal of cancer research and clinical oncology*. 2020;146(3):711-20.
40. Lou J, Li Y, Liang K, Guo Y, Song C, Chen L, et al. Hypofractionated radiotherapy as a salvage treatment for recurrent hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multi-center analysis. *BMC cancer*. 2019;19(1):668.
41. Pao TH, Hsueh WT, Chang WL, Chiang NJ, Lin YJ, Liu YS, et al. Radiotherapy for inferior vena cava tumor thrombus in patients with hepatocellular carcinoma. *BMC cancer*. 2019;19(1):560.
42. Li Y, Liu F, Yang L, Meng Y, Li A, Pan M. External-beam radiation therapy versus surgery in the treatment of hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombi. *Asia-Pacific journal of clinical oncology*. 2019;15(6):316-22.
43. Komatsu S, Kido M, Asari S, Toyama H, Ajiki T, Demizu Y, et al. Particle radiotherapy, a novel external radiation therapy, versus liver resection for hepatocellular carcinoma accompanied with inferior vena

- cava tumor thrombus: A matched-pair analysis. *Surgery*. 2017;162(6):1241-9.
44. Chun YH, Ahn SH, Park JY, Kim DY, Han KH, Chon CY, et al. Clinical characteristics and treatment outcomes of hepatocellular carcinoma with inferior vena cava/heart invasion. *Anticancer Res*. 2011;31(12):4641-6.
45. Jun CH, Sim DW, Kim SH, Hong HJ, Chung MW, Cho SB, et al. Risk factors for patients with stage IVB hepatocellular carcinoma and extension into the heart: prognostic and therapeutic implications. *Yonsei Med J*. 2014;55(2):379-86.
46. Wong L, Bozhilov K, Hernandez B, Kwee S, Chan O, Ellis L, et al. Underlying liver disease and advanced stage liver cancer are associated with elevated neutrophil-lymphocyte ratio. *Clin Mol Hepatol*. 2019;25(3):305-16.
47. Arii S, Tanaka J, Yamazoe Y, Minematsu S, Morino T, Fujita K, et al. Predictive factors for intrahepatic recurrence of hepatocellular carcinoma after partial hepatectomy. *Cancer*. 1992;69(4):913-9.
48. Izumi R, Shimizu K, Ii T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. *Gastroenterology*. 1994;106(3):720-7.
49. Lise M, Bacchetti S, Da Pian P, Nitti D, Pilati PL, Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. *Cancer*. 1998;82(6):1028-36.
50. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. *Ann Surg*. 2002;235(3):373-82.
51. Tse RV, Guha C, Dawson LA. Conformal radiotherapy for hepatocellular carcinoma. *Crit Rev Oncol Hematol*. 2008;67(2):113-23.
52. Rim CH, Yang DS, Park YJ, Yoon WS, Lee JA, Kim CY. Effectiveness of high-dose three-dimensional conformal radiotherapy in hepatocellular carcinoma with portal vein thrombosis. *Japanese journal of clinical oncology*. 2012;42(8):721-9.
53. Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. *Am J Clin Oncol*. 2006;29(6):568-75.
54. Rim CH, Yoon WS. Leaflet manual of external beam radiation therapy for hepatocellular carcinoma: a review of the indications, evidences, and clinical trials. *OncoTargets and therapy*. 2018;11:2865-74.
55. Rim CH, Kim CY, Yang DS, Yoon WS. Comparison of radiation therapy modalities for hepatocellular carcinoma with portal vein thrombosis: A meta-analysis and systematic review. *Radiother Oncol*. 2018;129(1):112-22.
56. Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. *Journal of hepatology*. 2000;32(5):865-71.
57. Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. *International journal of radiation oncology, biology, physics*. 2010;76(3 Suppl):S3-9.
58. Choi C, Yoo GS, Cho WK, Park HC. Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. *World J Gastroenterol*. 2019;25(20):2416-29.

59. Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. *J Clin Invest*. 2014;124(2):687-95.
60. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *Jama*. 2000;283(15):2008-12.
61. National Comprehensive Cancer Network (NCCN). NCCN Levels of Evidence and Consensus for Recommendations. accessed Aug 21th, 2020. available at: <https://www.nccn.org/professionals/development.aspx>.

Figure legends

Figure 1. Study inclusion plot

Figure 2. Forest plots of 1-year (A) and 2-year overall survival rates (B); forest plot of the 1-year overall survival rate according to extrahepatic metastasis rate (C); funnel plot of the 1-year (left) and 2-year overall survival rate on pooled analyses (D). Abbreviations: OS, overall survival; EBRT, external beam radiation therapy; EHM, extrahepatic metastasis

Table 1. General data from the studies included in this meta-analysis.

First author	Patients (n)	Year of publication	Category	Affiliation	Patient recruitment years	Age (y), median (range)	HBV (%)	CPC A (%)	AFP ≥ 400 ng/mL (%) or median (range)	PVT (%)	Extrahepatic metastases (%)	Complete resection	Funding
Zhang-1 (adjuvant TACE)	56	2019	Surgery	Eastern Hepatobiliary Surgery Hospital, VI division, China	2002–2015	50.5 (46.0–58.5)	89.3%	100%	39.3%	0.0%	LNM 10.7%		Government
Zhang-2 (no TACE)	35		Surgery			53.0 (49.0–66.0)	82.9%	100%	65.7%	0.0%	LNM 11.4%		
Matsukuma	37	2020	Surgery	Yamaguchi Univ., Osaka cancer institute, Osaka Univ. hospital	1997–2017	66 (61–75)	HBV 43.2%; HCV 37.8%	72.9%	316 (29–8968) ng/mL	100.0%	32.4%	67.6% (R0 or 1)	No funding
Kasai	39	2017	Surgery	Kyoto University	1996–2015	55 (49–67)	HBV 28%; HCV 36%	77%			26.0%	79% (R0 or 1)	N/A
Kokudo	13	2014	Surgery	Tokyo University	1994–2011	61.8 (57.4–66.2)	HBV 46%; HCV 38%	85%	22812 ng/mL	77.0%	0.0%	69% (R0)	No funding
Wakayama	13	2013	Surgery	Hokkaido University, Japan	1990–2012	Mean 63.4 +/- 11.8	HBV 53.8%; HCV 15.4%	100%			61.5%	38.5% (R0 or 1)	No funding
Li	13	2013	Surgery	Eastern Hepatobiliary Surgery Hospital, third division, China	1997–2009	49.7 (35–72)		100%		0.0%	0.0%	76.9% (completely resected)	Government
Wang	25	2013	Surgery	Eastern Hepatobiliary Surgery Hospital, second division, China	2000–2010	Mean 48.5 +/- 11.6	100.0%	100%	68% (>1000 ng/mL)	48.0%	0.0%		No funding
Liu	65 [†]	2012	Surgery	Sun Yat-Sen University, China	2000–2009	52.6 +/- 4.6	84.6%	A and B 75.4%	Mean 391.8 +/- 48.9 ng/mL	100.0%	0.0%		No funding
Koo	42	2010	EBRT	Asan Medical Center, Korea	2004–2006	Mean 54 +/- 8	83.3%	61.9%	47.6% (>1000 ng/mL)	45.2%		RT method (median or prescribed EQD2) 3DCRT (48.8 Gy)	Academic
Duan	11	2015	EBRT	General Hospital of Chinese People's Liberation Army, China	2005–2008	53 (30–74)	100.0%		1105 (2–24200) ng/mL	0.0%	81.8%	3DCRT (60 Gy)	Government
Rim	49	2020	EBRT	Six centers in Korea	2009–2016	59 (35–75)	77.6%	83.7%	311.6 (2.1–155041) ng/mL	65.3%	LNM 8.2%	3D or IMRT (46.7, 35.4–71.5)	Government

Hou-1	37	2012	EBRT	Zhongsan Hospital, Fudan University, China	2000–2009			86.5%	46.0%	0.0%	LNM 94.6%	2D or 3D (50 Gy)	No funding
Hou-2 (accompanying PVT) Igaki	18		EBRT							100.0%	LNM 88.2%		
	18	2008	EBRT	Tokyo Univ, Japan	1990–2006	70 (45–81)	HBV (16.7%); HCV (72.2%)	44.4%	16.5 (1– 136260) ng/mL			3D (50, 30– 60)	Government
Li-1	57	2019	EBRT	Eastern Hepatobiliary Surgery Hospital, Shanghai, China	2004–2016	Mean 53.6 +/- 12.3	84.2%		82.5%	24.6%	LNM 10.5%	3D or IMRT (46–60 Gy)	Government
Li-2 (surgery)	51		Surgery			Mean 51.7 +/- 9.8	92.2%		78.4%	11.8%	LNM 5.9%	(Surgery arm)	
Komatsu-1	19	2017	EBRT	Kobe University, Japan	2001–2016	Mean 68		57.9%	304 (2.2– 15440) ng/mL	31.6%	26.3%	Proton and carbon (73– 91)	N/A
Komatsu-2 (surgery)	19		Surgery			Mean 67		89.5%	148 (3.0– 90140) ng/mL	57.9%	26.3%	(Surgery arm)	
Sekino	21	2020	EBRT	Tsukuba Univ., Japan	2005–2014	73 (50–82)	HCV 61.9%; HBV 14.3%	57.1%	52.4%	33.3%	0.0%	Proton (72.6, 50–74)	Government
Lou	75	2019	EBRT	Shanghai Wujung, Guandong Nongken, Shanghai Jiading hospital	2008–2016	53 (23–75)	92.0%	88.0%	41.3%		LNM 7.3% distant mets. 28%	HFRT (~44, 32.5–56)	Academic
Pao	42	2019	EBRT	National Cheng Kung University Hospital, Taiwan	2007–2018	63 (40–92)	HBV 64.2%; HCV 33.3%	59.5%			LNM 19%; lung mets 23.8%	3D or IMRT (48.8, 3.3– 67.1)	Government

Upper case M prefix denotes median value; [†]include 17 right hepatic vein invasion cases

Abbreviations: HBV, hepatitis B virus; CPC, Child-Pugh class; AFP, alpha-fetoprotein; PVT, portal vein thrombosis; EBRT, external beam radiotherapy; TACE, transarterial chemoembolization; HFRT, hypofractionated radiotherapy; LNM, lymph node metastases; HCV, hepatitis C virus; 3DCRT, 3-dimensional conformal radiotherapy; IMRT, intensity modulated radiotherapy.

First author	Patients (n)	Follow-up, median (months)	OS, median (months)	OS 1-year	OS, 2-year	Factors related to OS	First progression	Grade ≥3 complication	Complete resection	Peri-operative mortality	Pre- or combined treatments	Post-surgery or radiotherapy treatments
Zhang-1 (adjuvant TACE)	56			73.2%	55.4%							TACE (100%)
Zhang-2 (no TACE)	35			48.6%	25.7%							
Matsukuma	37	13 (9.5–27.5)	13.8	59.5%	35.1%	Age, residual tumor in liver	Liver (40.5%); Lung (13.5%)	17.9%	67.6% (R0 or 1)	90 day: 5.4%	TACE (16.2%); HAIC (8.1%)	CTx (10.8%); HAIC (8.1%); RT (2.7%)
Kasai	39		15.2	64.0%	38.5%	Preop HAIC, Extracorporeal circulation, extrahepatic mets.	Liver (27.0%); Lung (35.1%);	67.0%	79% (R0 or 1)	30-day: 5%	TACE or TAI (28.5%); HAIC (20.5%); RT (7.7%)	CTx (17.9%); sorafenib (10.3%); HAIC (10.3%)
Kokudo	13	No dropout	16.7	84.6%	30.7%		Liver (61.5%); Lung (30.7%)		69% (R0)	90 day: 7.6%		Sorafenib (15.4%); TACE (30.8%); re-resection (23.1%)
Wakayama	13	11.2 (1.8–51.8)	15.3	50.4%	23.1%		Liver (61.5%); Lung (53.8%)		38.5% (R0 or 1)	30-day: 0%		CTx (30.8%); TACE (7.7%); RT (7.7%)
Li	13	(1–6 years)	13.0	53.8%	15.4%		Liver (69.2%)		76.9% (completely resected)			TACE (69.2%); RFA (23.1%); RT (23.1%)
Wang-1	25		19.0	68.0%	28.0%	Multiple tumors, surgery (vs. TACE, non-local Tx.)		8.0%				TACE and/or RT (60%); RFA (8%); re-resection (4%)
Liu	65	No dropouts	17.0	80.0%	14.7%							CTx (100%), TACE
									CR/PR/RR; LC	RILD		
Koo	42		11.7	47.7%	42.8%	CPC, PVT, IVCT progression		0.0%	14.3/28.6/42.9% LC: 71.4%	None	TACE (100%)	
Duan	11	3 dropouts	21.0	54.5%	45.0%			0.0%	18.2/54.5/72.7% LC: 90.9%		TACE (100%)	Sorafenib (45.4%); CTx. (18.2%)
Rim	49	9.3 (1.1–119)	10.1	43.5%	30.1%	AFP, multiple tumor, hospital size	Liver (44.9%); Lung (42.9%)	GI 0%; ascites 2%; varices 2%; LFT 30.6%; blood	LC: 85.7%	2.0%	TACE (26.5%); HAIC (28.6%)	TACE (18.4%); sorafenib (28.6%); HAIC (22.4%)

								count	26.5%				
Hou-1	37	10 (1.5–75)	17.4	67.6%	31.4%			0.0%	62.2/24.3/86.5; LC 86.5%	None			
Hou-2 (accompanying PVT)	18		8.5	41.7%	17.4%			0.0%		None			
Igaki	18	No dropout	5.6	33.3%	11.1%			NA	11.1/15.4/26.4; LC 91.7%	None	TACE (72.2%); surgery (27.8); RFA or PEI (38.9%)		
Li-1	57	14.5	12.8	57.9%	24.6%			0.0%		None	Any prior therapy (36.8%)		
Li-2 (surgery)	51		14.5	58.8%	21.6%			3.9%			Any prior therapy (23.5%)		
Komatsu-1	19	No dropout		68.0%	36.8%			0.0%	LC 84%	None			
Komatsu-2 (surgery)	19			34.0%	10.5%			26.3% 1 grade 5 case	LC 95%				
Sekino	21	21 (4–120)	21.0	62.0%	33.0%	Multiple tumor (UVA)		0.0%	CR: 33.3%; LC: 100%		TACE (57.1%); surgery (14.2%)	62% received post-radiotherapy treatment. (e.g. CTx., TACE)	
Lou	75	12 (3–40)	10.0	38.7%	13.3%	CPC, multiple tumors, distant mets, only TT in target, low RT dose (UVA)		0.0%	22.7/73.3/96%; LC: 100%	None			
Pao	42	4.4 (0.3–55.9)	6.6	30.0%	19.0%	CPC, LN mets, lung mets, IVC response	Liver (21.5%); Lung (33.3%)	0%	RR: 47.6%		TACE (45.2%); RFA or PEI (26.2%); systemic Tx. (28.6%); surgery (23.8%)	Systemic treatment 50%; TACE 14.3%; surgery 9.5%	

Upper case M prefix denotes median value

Abbreviations: OS, overall survival; TACE, transarterial chemoembolization; HAIC, hepatic arterial chemoembolization; CTx., chemotherapy; RT, radiotherapy; RFA, radiofrequency ablation; PEI, percutaneous ethanol injection; CR, complete remission; PR, partial response; RR, response rate; LC, local control; RILD, radiation-induced liver disease; AFP, alpha-fetoprotein; GI, gastrointestinal; LFT, liver function tests; UVA, univariate analysis; CPC, Child-Pugh class; PVT, portal vein thrombosis; IVCT, inferior vena cava thrombosis; TT, tumor thrombosis; LN, lymph node; IVC, inferior vena cava

Table 3. Pooled results of endpoints

	No. of studies	No. of patients	Heterogeneity p	I ² (%)	Heterogeneity	Pooled results (95% CI)	p-value (subgroup comparison)	Egger's p (trimmed value)*
<i>Child Pugh class A (%)</i>								
Surgery	9	250	0.02	55.8%	High	90.1% (80.2–95.4)	0.007	
EBRT	8	303	<0.001	77.0%	Very high	70.0% (56.9–80.5)		
<i>Accompanying PVT (%)</i>								
Surgery	9	314	<0.001	88.3%	Very high	40.8% (14.3–74.1)	0.815	
EBRT	8	254	<0.001	81.4%	Very high	36.2% (20.0–56.3)		
<i>Extrahepatic metastases (%)</i>								
Surgery	11	366	<0.001	73.7%	High	14.5% (7.6–25.8)	0.067	
EBRT	8	311	<0.001	88.5%	Very high	34.5% (16.5–58.3)		
<i>1-year OS</i>								
All studies	22	755	<0.001	66.4%	High	55.6% (48.9–62.1)		0.673
Surgery	11	389	0.009	57.7%	High	62.4% (53.8–70.3)	0.023	
EBRT	11	366	0.014	55.0%	High	48.8% (40.9–56.8)		
PVT <50%	11	367	0.361	8.7%	Low	60.2% (54.7–65.4)	0.801	
PVT ≥50%	6	201	<0.001	80.1%	High	57.8% (40.0–73.8)		
EHM <20%	10	385	0.004	63.3%	High	62.7% (53.8–70.9)	0.072	
EHM ≥20%	10	310	0.005	61.7%	High	50.6% (40.8–60.3)		
CPC A <80%	7	218	0.014	62.5%	High	51.8% (40.4–63.1)	0.641	
CPC A ≥80%	10	335	0.001	68.7%	High	55.6% (44.9–65.7)		
AFP <400 ng/mL [†]	10	417	<0.001	79.2%	Very high	55.7% (44.2–66.6)	0.617	
AFP ≥400 ng/mL	7	213	0.469	~0.0%	Very low	59.1% (52.2–65.6)		
<i>2-year OS</i>								
All studies	22	755	<0.001	59.3%	High	27.4% (22.3–33.1)		0.078 (32.3%)
Surgery	11	366	0.001	67.4%	High	26.9% (20.7–34.2)	0.913	
EBRT	11	389	0.031	49.6%	Moderate	27.5% (19.7–37.1)		
PVT <50%	11	367	0.016	54.1%	High	32.9% (25.8–40.9)	0.121	
PVT ≥50%	6	201	0.114	43.7%	Moderate	23.5% (16.0–33.2)		
EHM <20%	10	385	0.002	66.1%	High	27.8% (20.3–36.8)	0.801	
EHM ≥20%	10	310	0.034	50.2%	Moderate	26.3% (19.4–34.6)		
CPC A <80%	7	218	0.152	36.3%	Moderate	32.4% (24.8–41.1)	0.366	
CPC A ≥80%	10	335	<0.001	69.7%	High	26.5% (18.2–37.0)		
AFP <400 ng/mL [†]	10	417	<0.001	78.2%	High	27.5% (18.7–38.6)	0.925	
AFP ≥400 ng/mL	7	213	0.79	~0.0%	Very low	27.0% (21.4–33.4)		

Abbreviations: CI, confidence interval; OS, overall survival; EBRT, external beam radiotherapy; PVT, portal vein thrombosis; EHM, extrahepatic metastases; CPC, Child-Pugh class; AFP, alpha-fetoprotein

*Duval and Tweedie's trim and fill method for values with possible publication bias (Egger's p <0.1)

[†]Median value of ≥400 ng/mL or more than 50% of patients had AFP levels of ≥400 ng/mL

Table 4. Pooled results of selected secondary endpoints

	No. of studies	No. of patients	Heterogeneity p	I ² (%)	Heterogeneity	Pooled results (95% CI)
<i>EBRT response rates (EBRT studies only)</i>						
LC rate	8	272	0.053	49.7%	Moderate	87.2% (78.2–92.8)
CR rate	5	186	0.002	76.3%	Very high	27.9% (15.5–45.0)
RR rate	5	207	<0.001	89.8%	Very high	74.3% (46.9–90.5)
<i>First progression site (all available studies)</i>						
Liver	7	206	0.007	65.8%	High	43.2% (31.0–56.2)
Lung	6	193	0.074	50.2%	Moderate	34.0% (24.6–44.9)

Abbreviations: CI, confidence interval; EBRT, external beam radiotherapy; LC, local control; CR, complete remission; RR, response rate

(A)

1-year OS rate (%) (Surgery vs. EBRT)

(B)

2-year OS rate (%) (Surgery vs. EBRT)

(C)

1-year OS rate (%), EHM rate (<20% vs. >=20%)

(D)